The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).
Nam H. Dang
Honoraria - Pfizer
Research Funding - Pfizer
Michinori Ogura
No relevant relationships to disclose
Sylvie Castaigne
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Luis Fayad
No relevant relationships to disclose
Mats Jerkeman
No relevant relationships to disclose
John A. Radford
No relevant relationships to disclose
Antonio Pezzutto
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Douglas Allan Stewart
No relevant relationships to disclose
Michael Shnaidman
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Sharon Sullivan
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Erik Vandendries
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Kensei Tobinai
Research Funding - Pfizer
Rod Ramchandren
No relevant relationships to disclose
Paul A. Hamlin
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - GlaxoSmithKline; Pfizer; Seattle Genetics; Spectrum Pharmaceuticals
Eva Giné
No relevant relationships to disclose
Kiyoshi Ando
No relevant relationships to disclose